<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-INR-17013608</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-11-30</date_registration>
      <primary_sponsor>Shengjing Hospital affiliated to China Medical University </primary_sponsor>
      <public_title>Clinical application of autologous menstrual blood stromal stem cells combined with platelet-rich plasma transplantation on treating Asherman's syndrome and thin endometrium</public_title>
      <acronym />
      <scientific_title>Mechanism of menstrual blood stromal stem cells  transplantation on treating Asherman's syndrome</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-03-03</date_enrolment>
      <type_enrolment />
      <target_size>MenSCs+PRP:9;MenSCs:20;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=22944</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Asherman's syndrome?and thin endometrium</hc_freetext>
      <i_freetext>MenSCs+PRP:autologous transplantation of menstrual blood derived stromal stem cells (MenSCs) combined with platelet-rich plasma (PRP);MenSCs:autologous transplantation of menstrual blood derived stromal stem cells (MenSCs);</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Pingping Li</firstname>
        <middlename />
        <lastname />
        <address>36 Sanhao Street, Shenyang, Liaoning, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18940254782</telephone>
        <email>lipingping0227@163.com</email>
        <affiliation>Shengjing Hospital affiliated to China Medical University </affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Jichun Tan</firstname>
        <middlename />
        <lastname />
        <address>36 Sanhao Street, Shenyang, Liaoning, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18940251868</telephone>
        <email>tjczjh@163.com</email>
        <affiliation>Shengjing Hospital affiliated to China Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. aged 20-50 years;
2. infertility due to asherman's syndrome or thin endometrium of women;
3. failed to regenerate the endometrium in other treatments such as hormonal therapy, intrauterine device, aspirin or traditional chinese medicine. </inclusion_criteria>
      <agemin>20</agemin>
      <agemax>50</agemax>
      <gender>Female</gender>
      <exclusion_criteria>1. acute urogenital infection;
2. combined with other genital disease ingcluding hysteromyoma, adenomyosis, hydrosalpinx or body disease that could not bear pregnancy.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>endometrial thickness;endometrial morphology;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Goverment scientific research funding and hospital funding </source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-03-03</approval_date>
        <contact_name>Hong Wang</contact_name>
        <contact_address>36 Sanhao Street, Heping District, Shengyang, Liaoning, China</contact_address>
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>